Background: Human papillomavirus (HPV) vaccine was recommended in 2006 for routine vaccination of US females aged 11-12 years. Most vaccine used through 2014 was quadrivalent vaccine (4vHPV), which prevents HPV-6, -11, -16, and -18 infection. To evaluate vaccine impact, we measured HPV prevalence in the National Health and Nutrition Examination Survey (NHANES). Methods: We analyzed HPV DNA types detected in self-collected cervicovaginal specimens and demographic, sexual behavior, and self-reported vaccination data from females 14-34 years old. We estimated HPV prevalence in the prevaccine (2003-2006) and vaccine eras (2007-2010 and 2011-2014). Results: Among 14- to 19-year-olds, 4vHPV-type prevalence decreased from 11.5% (95% confidence interval [CI], 9.1%-14.4%) in 2003-2006 to 3.3% (95% CI, 1.9%-5.8%) in 2011-2014, when ≥1-dose coverage was 55%. Among 20- to 24-year-olds, prevalence decreased from 18.5% (95% CI, 14.9%-22.8%) in 2003-2006 to 7.2% (95% CI, 4.7%-11.1%) in 2011-2014, when ≥1-dose coverage was 43%. Compared to 2003-2006, 4vHPV prevalence in sexually active 14- to 24-year-olds in 2011-2014 decreased 89% among those vaccinated and 34% among those unvaccinated. Vaccine effectiveness was 83%. Conclusions: Within 8 years of vaccine introduction, 4vHPV-type prevalence decreased 71% among 14- to 19-year-olds and 61% among 20- to 24-year-olds. Estimated vaccine effectiveness was high. The decrease in 4vHPV-type prevalence among unvaccinated females suggests herd protection. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Human papillomavirus (HPV) vaccine was recommended in 2006 for routine vaccination of US females aged 11-12 years. Most vaccine used through 2014 was quadrivalent vaccine (4vHPV), which prevents HPV-6, -11, -16, and -18 infection. To evaluate vaccine impact, we measured HPV prevalence in the National Health and Nutrition Examination Survey (NHANES). Methods: We analyzed HPV DNA types detected in self-collected cervicovaginal specimens and demographic, sexual behavior, and self-reported vaccination data from females 14-34 years old. We estimated HPV prevalence in the prevaccine (2003-2006) and vaccine eras (2007-2010 and 2011-2014). Results: Among 14- to 19-year-olds, 4vHPV-type prevalence decreased from 11.5% (95% confidence interval [CI], 9.1%-14.4%) in 2003-2006 to 3.3% (95% CI, 1.9%-5.8%) in 2011-2014, when ≥1-dose coverage was 55%. Among 20- to 24-year-olds, prevalence decreased from 18.5% (95% CI, 14.9%-22.8%) in 2003-2006 to 7.2% (95% CI, 4.7%-11.1%) in 2011-2014, when ≥1-dose coverage was 43%. Compared to 2003-2006, 4vHPV prevalence in sexually active 14- to 24-year-olds in 2011-2014 decreased 89% among those vaccinated and 34% among those unvaccinated. Vaccine effectiveness was 83%. Conclusions: Within 8 years of vaccine introduction, 4vHPV-type prevalence decreased 71% among 14- to 19-year-olds and 61% among 20- to 24-year-olds. Estimated vaccine effectiveness was high. The decrease in 4vHPV-type prevalence among unvaccinated females suggests herd protection. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
HPV vaccine; human papillomavirus; prevalence; vaccine effectiveness; vaccine impact
Authors: Lester R Curtin; Leyla K Mohadjer; Sylvia M Dohrmann; Jill M Montaquila; Deanna Kruszan-Moran; Lisa B Mirel; Margaret D Carroll; Rosemarie Hirsch; Susan Schober; Clifford L Johnson Journal: Vital Health Stat 2 Date: 2012-05
Authors: Jessica A Kahn; Darron R Brown; Lili Ding; Lea E Widdice; Marcia L Shew; Susan Glynn; David I Bernstein Journal: Pediatrics Date: 2012-07-09 Impact factor: 7.124
Authors: Lauri E Markowitz; Gui Liu; Susan Hariri; Martin Steinau; Eileen F Dunne; Elizabeth R Unger Journal: Pediatrics Date: 2016-02-22 Impact factor: 7.124
Authors: Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Darron R Brown; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Laura A Koutsky; Eng Hseon Tay; Patricía Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret James; Teresa M Hesley; Eliav Barr Journal: J Infect Dis Date: 2009-04-01 Impact factor: 5.226
Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: David Mesher; Kate Soldan; Matti Lehtinen; Simon Beddows; Marc Brisson; Julia M L Brotherton; Eric P F Chow; Teresa Cummings; Mélanie Drolet; Christopher K Fairley; Suzanne M Garland; Jessica A Kahn; Kimberley Kavanagh; Lauri Markowitz; Kevin G Pollock; Anna Söderlund-Strand; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Elizabeth Unger; Sara L Thomas Journal: Emerg Infect Dis Date: 2016-10 Impact factor: 6.883
Authors: Sepehr N Tabrizi; Julia M L Brotherton; John M Kaldor; S Rachel Skinner; Bette Liu; Deborah Bateson; Kathleen McNamee; Maria Garefalakis; Samuel Phillips; Eleanor Cummins; Michael Malloy; Suzanne M Garland Journal: Lancet Infect Dis Date: 2014-08-05 Impact factor: 25.071
Authors: K Kavanagh; K G J Pollock; A Potts; J Love; K Cuschieri; H Cubie; C Robertson; M Donaghy Journal: Br J Cancer Date: 2014-04-15 Impact factor: 7.640
Authors: Kristine M Wylie; Todd N Wylie; Alison G Cahill; George A Macones; Methodius G Tuuli; Molly J Stout Journal: Am J Obstet Gynecol Date: 2018-05-05 Impact factor: 8.661
Authors: Elyse O Kharbanda; Gabriela Vazquez-Benitez; Heather S Lipkind; Sangini S Sheth; Jingyi Zhu; Allison L Naleway; Nicola P Klein; Rulin Hechter; Matthew F Daley; James G Donahue; Michael L Jackson; Alison Tse Kawai; Lakshmi Sukumaran; James D Nordin Journal: Obstet Gynecol Date: 2018-07 Impact factor: 7.661
Authors: Chelse Spinner; Lili Ding; David I Bernstein; Darron R Brown; Eduardo L Franco; Courtney Covert; Jessica A Kahn Journal: Pediatrics Date: 2019-01-22 Impact factor: 7.124
Authors: Julia Warner Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Michelle L Johnson Jones; Erin Whitney; Manideepthi Pemmaraju; Monica Brackney; Nasreen Abdullah; Mary Scahill; Rebecca M Dahl; Angela A Cleveland; Elizabeth R Unger; Lauri E Markowitz Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Jacqueline M Hirth; Yong-Fang Kuo; Jonathan M Starkey; Richard E Rupp; Tabassum H Laz; Mahbubur Rahman; Abbey B Berenson Journal: Vaccine Date: 2019-06-07 Impact factor: 3.641
Authors: Rayleen M Lewis; Lauri E Markowitz; Julia W Gargano; Martin Steinau; Elizabeth R Unger Journal: J Infect Dis Date: 2018-03-05 Impact factor: 5.226